How Lonza Is Outgrowing the CDMO Market with Bioconjugation, AI, and Regionalization

How Lonza Is Outgrowing the CDMO Market with Bioconjugation, AI, and Regionalization

From PharmaSource Podcast by Life Science Networks

May 31, 2026 · 29 min

About this episode

Christian Seufert discusses Lonza's strategy to outgrow the CDMO market through bioconjugation and innovative solutions.

"We want to outgrow the market, and we want to do it ethically." Christian Seufert , Head of Advanced Synthesis at Lonza and member of the executive committee, brings 20 years of experience from BASF's specialty chemical business. He leads a team applying 125 years of Lonza's chemistry expertise to manufacturing small molecules, highly potent APIs, and antibody-drug conjugates. In the latest PharmaSource podcast episode, Christian explains the ‘One Lonza’ strategy that positions the company to capture growth across the fastest-expanding CDMO segments, particularly bioconjugation, while addressing the industry's most persistent operational challenges: speed, data accessibility, and supply chain resilience. Read the full article

People in this episode

Guest: Christian Seufert

Topics covered

  • bioconjugation
  • AI
  • regionalization
  • CDMO market
  • supply chain resilience
  • operational challenges

Keywords

  • Lonza
  • CDMO
  • bioconjugation
  • AI
  • supply chain
  • operational challenges
  • pharmaceuticals

Mentioned in this episode

Organizations: Lonza, BASF, PharmaSource, CDMO

More episodes of PharmaSource Podcast

Explore listener stats, chart rankings, contacts and more on the PharmaSource Podcast podcast page.